[Skip to Content]
[Skip to Content Landing]
Invited Commentary
September 2015

Physician Estimations of the Risk of Gastrointestinal Stromal Tumor Recurrence—Not Accurate Enough?More Education May Be Needed

Author Affiliations
  • 1Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
JAMA Oncol. 2015;1(6):805-806. doi:10.1001/jamaoncol.2015.2404

The results from randomized clinical trials indicate that adjuvant imatinib improves recurrence-free survival when administered after surgery to patients with operable gastrointestinal stromal tumor (GIST), and in one trial1 3 years of treatment with adjuvant imatinib improved also overall survival compared with 1 year of imatinib. At present, 3 years of adjuvant therapy with imatinib is considered the standard of care for patients who have undergone surgery for high-risk GIST, unless the tumor harbors a mutation that confers resistance to imatinib (eg, PDGFRA exon 18 mutation D842V) or is wild-type for both KIT and PDGFRA.

×